Stock Scorecard



Stock Summary for Olema Pharmaceuticals Inc (OLMA) - $24.20 as of 3/2/2026 11:45:30 AM EST

Total Score

9 out of 30

Safety Score

41 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for OLMA

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for OLMA

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for OLMA

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for OLMA

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for OLMA (41 out of 100)

Stock Price Rating (Max of 10) 7
Historical Stock Price Rating (Max of 10) 3
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for OLMA

Citi, Stifel Bullish on Olema (OLMA) Despite COO Departure 2/28/2026 2:52:00 AM
Olema earnings on deck: Biotech faces widening loss ahead of key data 2/27/2026 2:52:00 PM
20,000-share Form 144 filed for Olami Medical (NASDAQ: OLMA) 2/25/2026 2:52:00 AM
Olema Pharmaceuticals CEO Spotlights Phase 3 Palazestrant Trials, KAT6 Program at Citi Summit 2/24/2026 9:52:00 AM
OLMA Financials: Income Statement, Balance Sheet & Cash Flow 2/24/2026 2:51:00 AM
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference 2/23/2026 2:52:00 AM
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference 2/20/2026 5:01:00 PM
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference 2/20/2026 4:40:00 PM
Stifel initiates coverage on Olema Pharmaceuticals (OLMA) with buy rating 2/18/2026 12:27:00 AM
From Olema to Insmed: Do These Soaring Biotechs Still Present a Good Investment Opportunity? 2/16/2026 1:57:00 AM

Financial Details for OLMA

Company Overview

Ticker OLMA
Company Name Olema Pharmaceuticals Inc
Country USA
Description Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company is headquartered in San Francisco, California.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 9/30/2025
Next Earnings Date 3/17/2026

Stock Price History

Last Day Price 24.20
Price 4 Years Ago 2.45
Last Day Price Updated 3/2/2026 11:45:30 AM EST
Last Day Volume 1,491,221
Average Daily Volume 1,245,612
52-Week High 36.26
52-Week Low 2.86
Last Price to 52 Week Low 746.15%

Valuation Measures

Trailing PE N/A
Industry PE 26.08
Sector PE 46.86
5-Year Average PE -6.73
Free Cash Flow Ratio 55.00
Industry Free Cash Flow Ratio 12.68
Sector Free Cash Flow Ratio 25.71
Current Ratio Most Recent Quarter 8.03
Total Cash Per Share 0.44
Book Value Per Share Most Recent Quarter 4.48
Price to Book Ratio 6.35
Industry Price to Book Ratio 50.08
Sector Price to Book Ratio 52.77
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 38.92
Sector Price to Sales Ratio Twelve Trailing Months 22.39
Analyst Buy Ratings 9
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 80,160,000
Market Capitalization 1,939,872,000
Institutional Ownership 110.12%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -33.95%
Reported EPS 12 Trailing Months -1.76
Reported EPS Past Year -1.36
Reported EPS Prior Year -2.21
Net Income Twelve Trailing Months -149,957,000
Net Income Past Year -129,474,000
Net Income Prior Year -96,655,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 35,260,000
Total Cash Past Year 139,480,000
Total Cash Prior Year 68,539,000
Net Cash Position Most Recent Quarter 32,260,000
Net Cash Position Past Year 139,480,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 3,000,000
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 0.99
Total Stockholder Equity Past Year 408,964,000
Total Stockholder Equity Prior Year 253,895,000
Total Stockholder Equity Most Recent Quarter 307,488,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -134,673,000
Free Cash Flow Per Share Twelve Trailing Months -1.68
Free Cash Flow Past Year -104,510,000
Free Cash Flow Prior Year -83,727,000

Options

Put/Call Ratio 0.34
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.53
MACD Signal -0.64
20-Day Bollinger Lower Band 0.00
20-Day Bollinger Middle Band 0.00
20-Day Bollinger Upper Band 0.00
Beta 1.92
RSI 0.00
50-Day SMA 11.59
150-Day SMA 10.81
200-Day SMA 9.01

System

Modified 2/26/2026 5:00:52 AM EST